{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-035785","form_type":"8-K","ticker":"TARA","cik":"0001359931","company_name":"Protara Therapeutics, Inc.","filed_at":"2025-04-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.062079+00:00","generated_at":"2026-05-23T04:49:00.525009+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Protara reports 100% CR at any time in BCG-unresponsive NMIBC; 67% at 12 months","bullets":["BCG-Unresponsive: 100% CR at any time (5/5), 67% at 12 months (2/3) as of April 16, 2025 cutoff.","BCG-Naïve: 76% CR at any time (16/21), 43% at 12 months (3/7) in Phase 2 ADVANCED-2 trial.","No Grade 3+ treatment-related adverse events; most AEs were Grade 1, transient, and consistent with immunopotentiation.","Company on track to present interim data from ~25 six-month evaluable BCG-Unresponsive patients by end of 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-035785","json":"https://secwatch.observer/filing/0001213900-25-035785.json","markdown":"https://secwatch.observer/filing/0001213900-25-035785.md","text":"https://secwatch.observer/filing/0001213900-25-035785.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1359931/000121390025035785/0001213900-25-035785-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1359931/000121390025035785/ea0239689-8k_protara.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T04:49:00.525009+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}